Files
Download Full Text (283 KB)
Keywords
respiratory syncytial virus, Nirsevimab
Disciplines
Nursing
Description
In July 2023, the FDA approved Nirsevimab (Beyfortus), a monoclonal antibody that provides direct protection to infants against respiratory syncytial virus (RSV), a dangerous respiratory virus that is the leading cause of infant hospitalization in the United States (CDC, 2024). During RSV season (November 1- March 31), Nirsevimab is ordered before the infant is discharged. Parents often have questions about Nirsevimab that they direct to the bedside RN.
The purpose of this evidence-based project was to inquire if a nursing gap in knowledge existed in providing parental education on Nirsevimab based on the novelty of this vaccine. Would a comprehensive evidence-based reference guide regarding RSV and Nirsevimab (Beyfortus), compared to vaccination instructions alone, improve confidence in providing parental education?
Publication Date
5-2025
Recommended Citation
Nowak J, Drabek A, Killich T, Kalasky A. The utilization of a reference guide to promote nurse confidence in providing parental education about Nirsevimab vaccine. Presented at Corewell Health William Beaumont University Hospital; 2025 May 6-12; Royal Oak, MI.
Comments
Nurses Week at Corewell Health William Beaumont University Hospital, Royal Oak, MI, May 6-12, 2025.